Samsung Biologics Co.,Ltd. (207940.KS)
KRW 1059000.0
(3.52%)
KRW 1059000.0
(3.52%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 16046.19 Billion KRW | -3.23% |
| 2022 | 16582.05 Billion KRW | 108.06% |
| 2021 | 7970.01 Billion KRW | 24.06% |
| 2020 | 6424.2 Billion KRW | 8.67% |
| 2019 | 5911.62 Billion KRW | -1.15% |
| 2018 | 5980.4 Billion KRW | -16.74% |
| 2017 | 7183.09 Billion KRW | -4.65% |
| 2016 | 7533.01 Billion KRW | 26.38% |
| 2015 | 5960.49 Billion KRW | 339.66% |
| 2014 | 1355.69 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 16342.85 Billion KRW | -1.09% |
| 2024 Q1 | 16523.19 Billion KRW | 2.97% |
| 2023 Q2 | 15701.8 Billion KRW | -4.15% |
| 2023 Q3 | 15887.67 Billion KRW | 1.18% |
| 2023 Q4 | 16046.19 Billion KRW | 1.0% |
| 2023 FY | 16046.19 Billion KRW | -3.23% |
| 2023 Q1 | 16381.7 Billion KRW | -1.21% |
| 2022 FY | 16582.05 Billion KRW | 108.06% |
| 2022 Q4 | 16582.05 Billion KRW | 3.05% |
| 2022 Q3 | 16091.75 Billion KRW | 2.76% |
| 2022 Q1 | 7998.2 Billion KRW | 0.35% |
| 2022 Q2 | 15659.44 Billion KRW | 95.79% |
| 2021 Q2 | 6611.01 Billion KRW | 2.04% |
| 2021 Q4 | 7970.01 Billion KRW | 4.95% |
| 2021 Q1 | 6479.1 Billion KRW | 0.85% |
| 2021 FY | 7970.01 Billion KRW | 24.06% |
| 2021 Q3 | 7594.3 Billion KRW | 14.87% |
| 2020 Q1 | 5944.97 Billion KRW | 0.56% |
| 2020 Q2 | 6032.87 Billion KRW | 1.48% |
| 2020 Q3 | 6137.19 Billion KRW | 1.73% |
| 2020 FY | 6424.2 Billion KRW | 8.67% |
| 2020 Q4 | 6424.2 Billion KRW | 4.68% |
| 2019 Q4 | 5911.62 Billion KRW | 2.19% |
| 2019 FY | 5911.62 Billion KRW | -1.15% |
| 2019 Q3 | 5785.05 Billion KRW | -0.71% |
| 2019 Q2 | 5826.64 Billion KRW | -1.04% |
| 2019 Q1 | 5887.96 Billion KRW | -1.55% |
| 2018 FY | 5980.4 Billion KRW | -16.74% |
| 2018 Q1 | 7251.32 Billion KRW | 0.95% |
| 2018 Q2 | 7451.63 Billion KRW | 2.76% |
| 2018 Q3 | 7419.12 Billion KRW | -0.44% |
| 2018 Q4 | 5980.4 Billion KRW | -19.39% |
| 2017 Q2 | 7115.04 Billion KRW | -1.44% |
| 2017 Q1 | 7218.86 Billion KRW | -4.17% |
| 2017 FY | 7183.09 Billion KRW | -4.65% |
| 2017 Q3 | 7108.29 Billion KRW | -0.09% |
| 2017 Q4 | 7183.09 Billion KRW | 1.05% |
| 2016 FY | 7533.01 Billion KRW | 26.38% |
| 2016 Q4 | 7533.01 Billion KRW | 0.0% |
| 2015 FY | 5960.49 Billion KRW | 339.66% |
| 2014 FY | 1355.69 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ORIENT BIO Inc. | 96.98 Billion KRW | -16444.554% |
| Green Cross Holdings Corporation | 3737.7 Billion KRW | -329.306% |
| Green Cross Holdings Corporation | 2643.31 Billion KRW | -507.048% |
| Pharmicell Co., Ltd. | 99.19 Billion KRW | -16077.023% |
| Green Cross Corporation | 2643.31 Billion KRW | -507.048% |
| GeneOne Life Science, Inc. | 151 Billion KRW | -10526.078% |
| Celltrion, Inc. | 19917.53 Billion KRW | 19.437% |
| SK bioscience Co.,Ltd. | 1852.43 Billion KRW | -766.22% |
| SK Biopharmaceuticals Co., Ltd. | 723.17 Billion KRW | -2118.868% |
| Prestige BioPharma Limited | 711.72 Billion KRW | -2154.565% |